-
Disulfiram in Cancer Research: Proteasome, Pyroptosis, and B
2026-07-15
Explore how Disulfiram, a dopamine β-hydroxylase inhibitor, uniquely advances cancer research by linking proteasome inhibition with emerging pyroptosis pathways. This article delivers an advanced assay-focused analysis, bridging mechanistic insight with practical lab protocol guidance.
-
Inflammation in Ischemic Stroke: Biomarkers and Treatment Ad
2026-07-15
Xiao et al. (2025) present a comprehensive review of neuroinflammation’s dual role in ischemic stroke (IS), emphasizing the complexity of immune responses from biomarker discovery to therapeutic strategies. Their synthesis integrates fragmented insights and highlights how inflammatory modulation could enhance both diagnostic precision and patient outcomes.
-
Translational Rigor: ARCA EGFP mRNA and the Next Wave of mRN
2026-07-14
Explore how ARCA EGFP mRNA—a next-generation, anti-reverse capped reporter—empowers translational researchers to optimize, validate, and de-risk mRNA delivery strategies in mammalian systems. This article bridges molecular design, competitive benchmarking, and the latest breakthroughs in biodegradable LNP innovation, providing a forward-thinking playbook for accelerating gene expression assays and therapeutic translation.
-
WEHI-539: Precision BCL-XL Inhibitor Workflows for Apoptosis
2026-07-14
WEHI-539 stands out as a selective BCL-XL inhibitor, enabling high-fidelity dissection of apoptotic pathways and chemoresistance in cancer stem cells. This article delivers actionable protocols, troubleshooting strategies, and insight into advanced applications that make WEHI-539 indispensable for apoptosis and cancer biology research.
-
Everolimus (RAD001) in Cancer Research: Applied Workflows &
2026-07-13
Everolimus (RAD001) is a benchmark mTOR pathway inhibitor, enabling precision in apoptosis assays and cancer cell proliferation studies. This guide offers detailed protocols, troubleshooting advice, and workflow optimizations—empowering researchers to unlock the full potential of Everolimus for translational cancer biology.
-
Human Gastrin I Peptide: Precision in GI Physiology Research
2026-07-13
Harnessing the high-purity human Gastrin I peptide from APExBIO enables rigorous modeling of gastric acid secretion and CCK2 receptor signaling in advanced organoid systems. This article delivers actionable protocols, workflow enhancements, and troubleshooting strategies—bridging recent organoid breakthroughs with translational gastrointestinal research.
-
Auranofin (SKU B7687): Advancing Redox and Apoptosis Assays
2026-07-12
This article translates real laboratory scenarios into best-practice guidance for using Auranofin (SKU B7687) in cell viability, proliferation, and cytotoxicity assays. Drawing on validated protocols and recent literature, it demonstrates how APExBIO’s Auranofin delivers reproducible results, robust thioredoxin reductase inhibition, and clear mechanistic endpoints for cancer and antimicrobial research.
-
IKK/β-TrCP2 Cascade Regulates TFEB Degradation via Phosphory
2026-07-10
This study delineates a phosphorylation-ubiquitination cascade governing TFEB stability, identifying IKK as a key kinase that flags TFEB for β-TrCP2-mediated ubiquitination and degradation. The findings clarify a distinct regulatory axis for TFEB independent of canonical mTORC1 control, with implications for autophagy, neurodegeneration, and protein phosphorylation analysis.
-
A Tunable Human Intestinal Organoid System: Self-Renewal and
2026-07-09
This study introduces a human intestinal organoid platform that achieves a controlled balance between stem cell self-renewal and differentiation using small molecule modulators. The innovation enables scalable, diverse organoid cultures for advanced disease modeling and high-throughput applications.
-
Angiotensin II–HIF-1α-HILPDA Axis Suppresses Ferroptosis in
2026-07-09
This study reveals that local angiotensin II drives radioresistance in nasopharyngeal carcinoma (NPC) by suppressing ferroptosis through the HIF-1α-HILPDA axis. These mechanistic insights highlight new targets for radiosensitization strategies and provide a framework for advanced translational research.
-
Redefining In Vitro Drug Response: Insights from Fractional
2026-07-08
Schwartz's dissertation introduces a refined framework for evaluating anticancer drug responses in vitro, emphasizing the distinction between relative and fractional viability metrics. This nuanced approach allows researchers to disentangle proliferative arrest from cell death, improving assay interpretation and informing better experimental design in cancer drug research.
-
Early Pheromone Perception Drives Neurodegeneration in C. el
2026-07-08
Peng et al. (2023) reveal that early-life exposure to specific pheromones in C. elegans remodels neurodevelopment and accelerates adult neurodegeneration by modulating neuronal signaling and autophagy pathways. This work highlights a direct link between developmental chemical cues and later-life neuronal health, providing new insights for neurodegeneration research.
-
D-Luciferin Sodium Salt: Precision Bioluminescence for Oncol
2026-07-07
D-Luciferin sodium salt revolutionizes ATP-dependent bioluminescence assays, enabling sensitive, non-invasive monitoring of cell viability and metabolism in real time. Its robust performance in advanced workflows—such as programming CAR macrophages with mRNA-LNPs for cancer immunotherapy—positions it as a transformative substrate for both fundamental and translational oncology research.
-
DMXAA (Vadimezan): Precision Disruption in Cancer Biology Re
2026-07-07
DMXAA (Vadimezan) stands out as a potent apoptosis inducer in tumor endothelial cells and an anti-angiogenic agent targeting VEGFR2 signaling. This article delivers practical, data-driven workflows, protocol enhancements, and troubleshooting insights—directly informed by recent innovations in nanomedicine and innate immunity amplification.
-
Homoharringtonine: Cytotoxic Alkaloid Workflows in Cancer &
2026-07-06
Homoharringtonine stands out as a cytotoxic alkaloid that bridges robust protein synthesis inhibition in leukemia research with rapid SARS-CoV-2 clearance in antiviral models. Learn how APExBIO’s compound unlocks advanced assay designs, protocol optimizations, and troubleshooting strategies for cross-domain research.